Ribonucleotide reductase, the rate-
limiting enzyme for
de novo DNA synthesis, is a common target for chemotherapy. Its increased activity in cancer cells is associated with malignant transformation and proliferation.
1 Trimidox is a specific ribonucleotide reductase inhibitor that reduces levels of dGTP and dCTP in HL-
60 cells, inducing apoptosis
via activation of caspases without altering the cell cycle distribution.
1,2 Trimidox inhibits growth of human promyelocytic leukemia HL-
60 cells with an IC
50 value of 35 μM.
1
